Streetbeat News

Stock Prices

HRST

LLY

MASI

MDGL

NVO

PFE

Tema has launched the Tema Cardiovascular and Metabolics ETF (HRST) focusing on companies like Novo Nordisk (NVO), which makes Ozempic, and Eli Lilly (LLY), maker of Mounjaro. Semaglutides, including Ozempic and Mounjaro, have shown significant weight loss and organ protection benefits. NVO's stock has surged 281% since Ozempic's 2019 launch, while LLY's shares jumped nearly 80% post-Mounjaro's 2022 launch. In contrast, Pfizer (PFE), without a semaglutide, has seen a 51% decline since December 2021. HRST aims to capitalize on the lucrative cardiovascular and obesity treatment market, also including companies like Masimo (MASI) and Madrigal Pharmaceuticals (MDGL).

Portfolio Pulse from Neil Dennis

November 21, 2023 | 1:55 pm

VFS

Wedbush analyst Daniel Ives has initiated coverage on VinFast Auto (NASDAQ:VFS) with an Outperform rating and set a price target of $12 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:53 pm

BURL

Burlington Stores, Inc. reported positive Q3 financial results and provided guidance, leading to an increase in its stock price.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:50 pm

AEO

American Eagle Outfitters' stock price is trading lower following the release of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:49 pm

SYM

Symbotic's stock price has increased following the announcement of their Q4 sales results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:46 pm

A

Agilent Technologies, Inc. reported better-than-expected financial results for Q4, leading to an increase in its stock price.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:45 pm

TCOM

Trip.com's stock is trading lower following the release of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:44 pm

ZM

Zoom Video Communications Inc (NASDAQ:ZM) reported Q3 financial results that exceeded estimates, with revenue of $1.14 billion and EPS of $1.29. The company saw a 7.5% year-over-year increase in enterprise revenue and a 67% increase in operating cash flow. Zoom ended the quarter with 219,700 enterprise customers, a 5% increase from the previous year, and raised its full-year revenue and earnings outlook. Despite the positive results, Barclays and Rosenblatt maintained their ratings with lowered and maintained price targets, respectively. After an initial post-earnings increase, Zoom's stock pulled back slightly.

Portfolio Pulse from Adam Eckert

November 21, 2023 | 1:43 pm

CNP

Morgan Stanley analyst Stephen Byrd has maintained an Overweight rating on CenterPoint Energy (NYSE:CNP) but reduced the price target from $28 to $27.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:42 pm

BRDG

Morgan Stanley analyst Michael Lapides has maintained an Overweight rating on Bridge Investment Group (NYSE:BRDG) but reduced the price target from $14 to $13.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:40 pm